Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 60


Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.

Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, Wennerberg K.

Mol Cancer. 2016 May 10;15(1):34. doi: 10.1186/s12943-016-0517-3.


Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2016 May 5. pii: S0302-2838(16)30080-X. doi: 10.1016/j.eururo.2016.04.019. [Epub ahead of print]


Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses.

Varghese FS, Kaukinen P, Gläsker S, Bespalov M, Hanski L, Wennerberg K, Kümmerer BM, Ahola T.

Antiviral Res. 2016 Feb;126:117-24. doi: 10.1016/j.antiviral.2015.12.012. Epub 2016 Jan 2.


Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.


Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.

Kulesskiy E, Saarela J, Turunen L, Wennerberg K.

J Lab Autom. 2016 Feb;21(1):27-36. doi: 10.1177/2211068215618869. Epub 2015 Dec 2.


MgcRacGAP inhibition stimulates JAK-dependent STAT3 activity.

van Adrichem AJ, Wennerberg K.

FEBS Lett. 2015 Dec 21;589(24 Pt B):3859-65. doi: 10.1016/j.febslet.2015.11.013. Epub 2015 Nov 19.


Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data.

Pokharel YR, Saarela J, Szwajda A, Rupp C, Rokka A, Lal Kumar Karna S, Teittinen K, Corthals G, Kallioniemi O, Wennerberg K, Aittokallio T, Westermarck J.

Mol Cell Proteomics. 2015 Dec;14(12):3274-83. doi: 10.1074/mcp.M115.050773. Epub 2015 Oct 23.


From drug response profiling to target addiction scoring in cancer cell models.

Yadav B, Gopalacharyulu P, Pemovska T, Khan SA, Szwajda A, Tang J, Wennerberg K, Aittokallio T.

Dis Model Mech. 2015 Oct 1;8(10):1255-64. doi: 10.1242/dmm.021105.


What is synergy? The Saariselkä agreement revisited.

Tang J, Wennerberg K, Aittokallio T.

Front Pharmacol. 2015 Sep 1;6:181. doi: 10.3389/fphar.2015.00181. eCollection 2015. Review.


Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening.

Duellman SJ, Zhou W, Meisenheimer P, Vidugiris G, Cali JJ, Gautam P, Wennerberg K, Vidugiriene J.

Assay Drug Dev Technol. 2015 Oct;13(8):456-65. doi: 10.1089/adt.2015.669. Epub 2015 Sep 18.


Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data.

Mpindi JP, Swapnil P, Dmitrii B, Jani S, Saeed K, Wennerberg K, Aittokallio T, Östling P, Kallioniemi O.

Bioinformatics. 2015 Dec 1;31(23):3815-21. doi: 10.1093/bioinformatics/btv455. Epub 2015 Aug 7.


Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles.

Szwajda A, Gautam P, Karhinen L, Jha SK, Saarela J, Shakyawar S, Turunen L, Yadav B, Tang J, Wennerberg K, Aittokallio T.

Chem Biol. 2015 Aug 20;22(8):1144-55. doi: 10.1016/j.chembiol.2015.06.021. Epub 2015 Jul 23.


KIFC1 is a novel potential therapeutic target for breast cancer.

Li Y, Lu W, Chen D, Boohaker RJ, Zhai L, Padmalayam I, Wennerberg K, Xu B, Zhang W.

Cancer Biol Ther. 2015;16(9):1316-22. doi: 10.1080/15384047.2015.1070980. Epub 2015 Jul 15.


Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.

Al-Ali H, Lee DH, Danzi MC, Nassif H, Gautam P, Wennerberg K, Zuercher B, Drewry DH, Lee JK, Lemmon VP, Bixby JL.

ACS Chem Biol. 2015 Aug 21;10(8):1939-51. doi: 10.1021/acschembio.5b00289. Epub 2015 Jun 24.


Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products.

Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T.

Nat Prod Rep. 2015 Aug;32(8):1249-66. doi: 10.1039/c5np00005j. Review.


Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.


Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.


TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples.

He L, Wennerberg K, Aittokallio T, Tang J.

Bioinformatics. 2015 Jun 1;31(11):1866-8. doi: 10.1093/bioinformatics/btv067. Epub 2015 Jan 31.


Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.

Yadav B, Wennerberg K, Aittokallio T, Tang J.

Comput Struct Biotechnol J. 2015 Sep 25;13:504-13. doi: 10.1016/j.csbj.2015.09.001. eCollection 2015.


Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening.

Vidugiriene J, Leippe D, Sobol M, Vidugiris G, Zhou W, Meisenheimer P, Gautam P, Wennerberg K, Cali JJ.

Assay Drug Dev Technol. 2014 Nov-Dec;12(9-10):514-26. doi: 10.1089/adt.2014.605.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk